FUJIFILM Diosynth Biotechnologies’ Post

🚀 Together for innovation: Charité - Universitätsmedizin Berlin and Bayer AG have unveiled plans for the Berlin Center for Gene and Cell Therapies, a new hub aimed at accelerating groundbreaking gene and cell therapies. 🌟 With substantial support from the German federal government and the State of Berlin, this initiative seeks to make advanced treatments more accessible to patients and establish Berlin as a leading biotech ecosystem. 🔬 The center will feature an incubator supporting #startups in developing innovative therapeutic approaches, complete with fully equipped lab spaces and GMP-certified production facilities. 🤝 Together, Charité and Bayer are committed to transforming promising research into real-world health solutions. 👉 Discover more about the thriving health economy in the Berlin Brandenburg Airport Region and the medicine of the future here: https://lnkd.in/egk3uZ74 #AirportRegionBB #Biotech #MedicalResearch #FutureOfMedicine

🚀 Announcement: Many of our staff are now members of the newly created Italian society for cell and gene therapy, SITGEC. Why has it been created? • 🌟 Groundbreaking Growth: To foster innovation in gene and cell therapy, a rapidly advancing field. • 🇮🇹 Italian Excellence: Italian scientists are internationally acclaimed for pioneering contributions since the '90s. • 🧬 Life-Changing Impact: Thousands, including many in Italy, benefit from advanced therapies for cancer, rare diseases, and more. • 🏥 Clinical Leadership: Italy has developed and trialed several ATMP drugs, with five already marketed in Europe/US! • 🤝 Collaboration & Growth: SITGEC is designed to support and expand these cutting-edge treatments. The creation of the Society is particularly timely, given that the upcoming ESGCT Congress will be held in Rome in October, where ReiThera will be participating as Platinum sponsors. #gmp #biotech #biotechnology #genetherapy #cellandgenetherapy

The latest developments, trials, regulations and industrial successes: 𝗲𝘃𝗲𝗿𝘆𝘁𝗵𝗶𝗻𝗴 𝘆𝗼𝘂 𝗻𝗲𝗲𝗱 𝘁𝗼 𝗸𝗻𝗼𝘄 𝘁𝗼 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗲 𝗶𝗻 #genetherapy 🧬 Follow us at the Advanced Therapies Congress, from March 19th to 20th in London, UK. The 𝗖𝗔𝗣𝗔𝗖𝗜𝗧𝗘𝗦 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝘁𝗲𝗮𝗺 and the TaRGeT - INSERM UMR1089 gene therapy laboratory will be presenting their unique translational expertise on the market ! 🔎 Our strength lies in the close collaboration between researchers, clinicians and engineers to deploy a cutting-edge and tailor-made approach: ✔ Comprehensive support in the development of your drug candidates. ✔ Advanced expertise covering process development and viral vector production, preclinical in vivo trials, preclinical and clinical immune monitoring. ✔ Access to specific experimental models and a wide range of cutting-edge assays If you are a pharmaceutical or biotechnology company and you want to take full advantage of innovations in this promising sector, while guaranteeing efficacy and compliance with regulations, our team is here to support you ! 🤝 🔬 ▶ Discover our range of expertises in gene therapy: https://lnkd.in/eT9-m32R Oumeya (Mia) Adjali, Caroline Le Guiner, Véronique Blouin-Tavel, Emilie Audran, Célia Couzinié, Héloïse Fonteneau, MabDesign Network, CHU de Nantes, Inserm Transfert, Nantes Université #adtherapies24 #research, #biotech, #innovation #engineering #collaboration 

We had an amazing time at ESACT, where cutting-edge advancements in cell technology were front and centre. Highlights from an incredible ESACT conference! Andreas Plückthun presented SHREAD (SHielded, REtargeted ADenovirus), a platform for in situ production of therapeutic proteins using virus-like particles without viral genes. SHREAD enables targeted delivery and expression of therapeutic antibodies, bispecific T-cell engagers, and cytokines in vivo, showing potential promise for precision medicine applications. Innovative talks on transposases for stable non-viral gene delivery showcased their potential for efficient and long-term integration of therapeutic genes. These solutions offer reduced immunogenicity and simpler production compared to traditional viral vectors, possibly paving the way for more accessible and safer gene therapies. Being with suppliers, partners, and familiar faces: ESACT provided a fantastic opportunity to catch up with many of our partners and old friends, as well as to meet new ones! #ESACT2024 #Biotechnology #GeneTherapy #CellTherapy #PrecisionMedicine #Innovation #Networking #Bioprocessing

Join me at Swiss Biotech Day to encourage collaborative dialogues on the future of biotech. Let's discuss how strategic partnerships can address industry challenges and drive innovation for better patient outcomes. 💡 Swiss Biotech Association #IworkforCSL #SwissBiotechDay #InnovationinBiotech

Sometimes the speed at which scientific research can happen is truly life changing. The covid vaccine was ready for use in under twelve months, the first #CRISPR cure was delivered only 10 years after CRISPR itself was discovered. Great article discussing the speed at which an anti-COVID antibody candidate was discovered and developed into Evusheld- an antibody treatment for immunocompromised individuals. Improving gene synthesis speed can decrease workflow times, saving invaluable time as seen in this important research from Seth Zost & team at Vanderbilt University Medical Center when they discovered a candidate anti-#SARSCoV2 antibody in just 78 days! 👉Page 40 of Drug Discovery World’s latest issue: https://lnkd.in/gbQgBqiJ #antibody #antibodydiscovery #DNA

Latest update from the Synthego Corporation team – Novel hfCas12Max nuclease!!! hfCas12Max is designed to streamline therapeutic development from Research to Clinical, underscoring our commitment to making advanced CRISPR technologies more accessible to our ANZ scientists. 🔬 Key Features of hfCas12Max for in-vitro/in-vivo CRISPR experiments: Superior Editing Efficiency: Engineered to maximise editing capabilities across various cell types. Minimized Off-Target Editing: Unparalleled high precision and accuracy compared to other common CRISPR nucleases. Broad PAM Sequence Recognition Profile: Expands your gene editing potential to wider genomic regions with high specificity. Compact Size: Easily packaged into lipid nanoparticles or adeno-associated viruses (AAVs), making it ideal for ex vivo and in vivo CRISPR-based therapies.    hfCas12Max pushes the boundaries of what’s possible and is now available to order! Gain exclusive access to this powerful nuclease. Note: hfCas12Max nuclease is intended for use exclusively with Synthego’s new hfCas12Max gRNA offering.  Happy gene editing ✂️🧬 https://lnkd.in/g8Wv_bTd #enablingdiscovery #synthego #CRISPR

🔹High Throughput Screening of Lipid Nanoparticles for Drug delivery to Immune Cells 🔹 Transduction and expansion of Natural Killer Cells 🔹 Multi Gene Editing of iPSCs with Novel Transfection Platform Solupore® 🔹 Optimizing Lentiviral Vector Production for Cell Therapies: Advancing Manufacturing Strategies

It's interesting to read this article and see the vocabulary that was originally used for military situations. "Target," "Payload," "Delivery System." More like they were building a military missile program than a biotech company. It really highlights the new more advanced therapies which have been described as "smart bombs for cancer," as opposed to the dreadful old chemotherapy which was basically just carpet bombing the enemy. first declared by Richard Nixon in 1971. it appears that the "War on Cancer" is escalating rapidly! #Regeneron #Biotech #Biotechnology #Cancer #Oncology Regeneron signs Mammoth gene editing deal worth $100M upfront https://lnkd.in/epKk65Ei

Join Our Webinar on in silico Gene Perturbation using scGPT! We live in an exciting time of biotech innovation. The ability to conduct experiments in silico using foundational models such as scGPT may transform how we generate therapeutic hypotheses, discover targets, and streamline the entire drug discovery process. Promising as foundational models may be, getting them to work can be a sobering experience—even if the code is available. Common challenges include adapting the model to new and general tasks, implementing new ideas like classifiers, resolving installation issues and dependencies, selecting the right GPU, and figuring out how to use your dataset. At Code Ocean, we've already solved these hurdles to make using scGPT easy and adaptable to your needs. In our upcoming webinar, we will show you how to get started with scGPT with minimal set-up time. We demonstrate an app for downloading public datasets, an app for extracting scGPT embeddings after in silico gene perturbations, and an app for downstream disease classification using our built-in MLFlow and GitHub Copilot-powered analysis in VSCode. Together with my colleague Dror Hilman and hosted by our partner from AION Labs Yair Benita, we'll show how you can seamlessly apply foundational models such as scGPT to your datasets, enabling you to explore new possibilities in drug discovery with greater efficiency and precision. Register now: https://lnkd.in/durtkW_z